Cargando…

Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data

BACKGROUND: Patients with unresectable and metastasized gastrointestinal stromal tumor (GIST) experienced a remarkable improvement of progression-free survival (PFS) and overall survival (OS) after the introduction of imatinib. Our hypothesis is that the outcomes of treatment with imatinib are even...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohammadi, Mahmoud, IJzerman, Nikki S., Hollander, Dide den, Bleckman, Roos F., Oosten, Astrid W., Desar, Ingrid M. E., Reyners, An K. L., Steeghs, Neeltje, Gelderblom, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191911/
https://www.ncbi.nlm.nih.gov/pubmed/37079223
http://dx.doi.org/10.1007/s11523-023-00960-y
_version_ 1785043549272670208
author Mohammadi, Mahmoud
IJzerman, Nikki S.
Hollander, Dide den
Bleckman, Roos F.
Oosten, Astrid W.
Desar, Ingrid M. E.
Reyners, An K. L.
Steeghs, Neeltje
Gelderblom, Hans
author_facet Mohammadi, Mahmoud
IJzerman, Nikki S.
Hollander, Dide den
Bleckman, Roos F.
Oosten, Astrid W.
Desar, Ingrid M. E.
Reyners, An K. L.
Steeghs, Neeltje
Gelderblom, Hans
author_sort Mohammadi, Mahmoud
collection PubMed
description BACKGROUND: Patients with unresectable and metastasized gastrointestinal stromal tumor (GIST) experienced a remarkable improvement of progression-free survival (PFS) and overall survival (OS) after the introduction of imatinib. Our hypothesis is that the outcomes of treatment with imatinib are even better nowadays compared with the registration trials that were performed two decades ago. To study this, we used real-life data from a contemporary registry. METHODS: A multicenter, retrospective study was performed by exploring clinical data from a prospective real-life clinical database, the Dutch GIST Registry (DGR). Patients with advanced GIST treated with first-line imatinib were included and PFS (primary outcome) and OS (secondary outcome) were analyzed. Results of our study were compared with published results of the European Organisation for Research and Treatment of Cancer (EORTC) 62005 trial, which marked the first era of imatinib in the treatment of GIST. RESULTS: Overall, 420 of the 435 patients treated with imatinib in the DGR had recorded response evaluation and were included in the analysis. During a median follow-up of 35.0 months (range 2.0–136.0), progression of GIST was eventually observed in 217 patients (51.2%). The DGR cohort showed a longer median PFS (33.0 months, 95% confidence interval [CI] 28.4–37.6) compared with the EORTC 62005 trial (an estimated PFS of 19.5 months). Additionally, the median OS of 68.0 months (95% CI 56.1–80.0) was longer than the exposed median OS (46.8 months) published in the long-term follow-up results of the EORTC 62005 trial (median follow-up duration 10.9 years). CONCLUSION: This study provides an update on outcomes of imatinib in the treatment of advanced GIST patients and demonstrates improved clinical outcomes since the first randomized studies of imatinib 2 decades ago. Furthermore, these results represent outcomes in real-world clinical practice and can serve as a reference when evaluating effectiveness of imatinib in patients with advanced GIST.
format Online
Article
Text
id pubmed-10191911
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-101919112023-05-19 Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data Mohammadi, Mahmoud IJzerman, Nikki S. Hollander, Dide den Bleckman, Roos F. Oosten, Astrid W. Desar, Ingrid M. E. Reyners, An K. L. Steeghs, Neeltje Gelderblom, Hans Target Oncol Original Research Article BACKGROUND: Patients with unresectable and metastasized gastrointestinal stromal tumor (GIST) experienced a remarkable improvement of progression-free survival (PFS) and overall survival (OS) after the introduction of imatinib. Our hypothesis is that the outcomes of treatment with imatinib are even better nowadays compared with the registration trials that were performed two decades ago. To study this, we used real-life data from a contemporary registry. METHODS: A multicenter, retrospective study was performed by exploring clinical data from a prospective real-life clinical database, the Dutch GIST Registry (DGR). Patients with advanced GIST treated with first-line imatinib were included and PFS (primary outcome) and OS (secondary outcome) were analyzed. Results of our study were compared with published results of the European Organisation for Research and Treatment of Cancer (EORTC) 62005 trial, which marked the first era of imatinib in the treatment of GIST. RESULTS: Overall, 420 of the 435 patients treated with imatinib in the DGR had recorded response evaluation and were included in the analysis. During a median follow-up of 35.0 months (range 2.0–136.0), progression of GIST was eventually observed in 217 patients (51.2%). The DGR cohort showed a longer median PFS (33.0 months, 95% confidence interval [CI] 28.4–37.6) compared with the EORTC 62005 trial (an estimated PFS of 19.5 months). Additionally, the median OS of 68.0 months (95% CI 56.1–80.0) was longer than the exposed median OS (46.8 months) published in the long-term follow-up results of the EORTC 62005 trial (median follow-up duration 10.9 years). CONCLUSION: This study provides an update on outcomes of imatinib in the treatment of advanced GIST patients and demonstrates improved clinical outcomes since the first randomized studies of imatinib 2 decades ago. Furthermore, these results represent outcomes in real-world clinical practice and can serve as a reference when evaluating effectiveness of imatinib in patients with advanced GIST. Springer International Publishing 2023-04-20 2023 /pmc/articles/PMC10191911/ /pubmed/37079223 http://dx.doi.org/10.1007/s11523-023-00960-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research Article
Mohammadi, Mahmoud
IJzerman, Nikki S.
Hollander, Dide den
Bleckman, Roos F.
Oosten, Astrid W.
Desar, Ingrid M. E.
Reyners, An K. L.
Steeghs, Neeltje
Gelderblom, Hans
Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data
title Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data
title_full Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data
title_fullStr Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data
title_full_unstemmed Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data
title_short Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data
title_sort improved efficacy of first-line imatinib in advanced gastrointestinal stromal tumors (gist): the dutch gist registry data
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191911/
https://www.ncbi.nlm.nih.gov/pubmed/37079223
http://dx.doi.org/10.1007/s11523-023-00960-y
work_keys_str_mv AT mohammadimahmoud improvedefficacyoffirstlineimatinibinadvancedgastrointestinalstromaltumorsgistthedutchgistregistrydata
AT ijzermannikkis improvedefficacyoffirstlineimatinibinadvancedgastrointestinalstromaltumorsgistthedutchgistregistrydata
AT hollanderdideden improvedefficacyoffirstlineimatinibinadvancedgastrointestinalstromaltumorsgistthedutchgistregistrydata
AT bleckmanroosf improvedefficacyoffirstlineimatinibinadvancedgastrointestinalstromaltumorsgistthedutchgistregistrydata
AT oostenastridw improvedefficacyoffirstlineimatinibinadvancedgastrointestinalstromaltumorsgistthedutchgistregistrydata
AT desaringridme improvedefficacyoffirstlineimatinibinadvancedgastrointestinalstromaltumorsgistthedutchgistregistrydata
AT reynersankl improvedefficacyoffirstlineimatinibinadvancedgastrointestinalstromaltumorsgistthedutchgistregistrydata
AT steeghsneeltje improvedefficacyoffirstlineimatinibinadvancedgastrointestinalstromaltumorsgistthedutchgistregistrydata
AT gelderblomhans improvedefficacyoffirstlineimatinibinadvancedgastrointestinalstromaltumorsgistthedutchgistregistrydata